Novo Nordisk, obesity and CagriSema

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
What went wrong with Novo Nordisk’s CagriSema obesity drug trial
The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares dropped to its lowest point since August 2023 after the disappointing trial r
Novo Nordisk: Why The Market Sell-Off On CagriSema Data May Be Justified
Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Learn more on NVO stock here.
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of 2025 that it hopes will show greater weight-loss, after posting disappointing late-stage trial data.
Novo Nordisk shares rebound despite disappointing CagriSema trial results
Investing.com -- Novo Nordisk (CSE: NOVOb ) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema.
Novo Nordisk shares plunge 24% after CagriSema obesity drug trial results
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point on Friday after reporting trial results that missed expectations.
Novo Nordisk shares plunge on the back of disappointing trial results
Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped out €90bn in market valuation on Friday. View on euronews
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading in opposite directions later this week after the former disappointed investors with its next-gen weight loss candidate,
Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
Will Novo Nordisk (NVO) Stock Recover To $145 Levels?
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
BioSpace5d
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...